Navigation Links
Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
Date:4/17/2008

SEATTLE, April 17 /PRNewswire/ -- The state's Life Sciences Discovery fund has awarded $2.2 million to establish a formal phase 1 clinical-trials program to test new therapies for solid tumors at Fred Hutchinson Cancer Research Center. Announced this evening, the grant is among the first funded by Washington's $350 million tobacco-lawsuit-settlement bonus.

Developing novel therapies targeted to treat solid tumors, in collaboration with local biotechnology and pharmaceutical firms, is the goal of the Hutchinson Center/University of Washington Cancer Consortium. Phase 1 trials are by definition the first testing of cancer therapies in humans. The purpose is to determine whether and how a drug works.

Traditionally, phase 1 studies have been primarily concerned with drug safety. However, with the increased knowledge of the molecular pathways involved in cancer development, an ever-increasing proportion of drugs initially tested in humans prove to be effective, even in the first patients treated.

"Phase 1 trials are critically important, require a high level of unique competencies and, if done correctly, can substantially speed the development of new therapies," said Martin (Mac) Cheever, M.D., director of solid-tumor research at the Hutchinson Center. "This is an outcome that can benefit the state's patients, industry and health care enterprises."

Initially, the program will use the funding to develop a highly efficient infrastructure for implementing early phase -- primarily industry sponsored -- cancer clinical trials, and to provide exploratory funds that will allow Consortium researchers to apply their expertise in cancer imaging and biomarkers to cancer drug development.

The program will be led by John Thompson, M.D., as director of the Consortium phase 1 program. Thompson will be responsible for scientific direction and facilitating new industry and other trial sponsorships.

"Standard therapy for cancer is clearly inadequate," Cheever said. "The best hope is the development of new targeted therapies. Thanks to ever-advancing technologies and expanding basic knowledge of cancer biology -- areas of exceptional strength in the consortium -- the opportunities for developing new therapies targeted to cancer cells have never been greater."

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

About the Life Sciences Discovery Fund

The Life Sciences Discovery Fund, a Washington State agency established in May 2005, makes grant investments in innovative life sciences research to benefit Washington and its citizens. For more information on the Life Sciences Discovery Fund, visit: http://www.lsdfa.org.

CONTACT

Dean Forbes

206-605-0311

dforbes@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cardiac Science to Present at the UBS Global Life Sciences Conference
8. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
9. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. Clarient to Present at the UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, ... addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization ... optimization products to the store is just one more way Shamangelic Healing supports ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the dentists ... dentistry is a fast-growing field as more patients are discovering the many different ways ... about the options currently available to them and which ones might work for their ...
(Date:4/29/2016)... Jupiter, FL (PRWEB) , ... April 29, 2016 ... ... it will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third ... than a century of churning cream into butter, Grassland Dairy Products, located in ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
(Date:4/27/2016)... Kan. , April 27, 2016  Bayer ... , a senior from the University of Florida ... of the Bayer Excellence in Communication Award (BECA). ... schools, which were awarded a total of $70,000 ... the last four years, Bayer has provided a ...
Breaking Medicine Technology: